Organic compounds -- part of the class 532-570 series inventions 01/09

20090030189 - Mtor gls and els, their small molecule mimetics and competitive inhibitors: The present invention relates generally to molecular mechanisms of mTOR-related human diseases. More specifically, the invention relates to two novel related polypeptides, the ER-localization sequence (ELS) and Golgi-localization sequence (GLS) along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.... Agent: University Of Medicine And Dentistry Of New Jersey Office Of Patents And Licensing

20090030190 - Sirna targeting 1-acylglycerol-3-phosphate o-acyltransferase 2 (agpat2): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090030191 - Process for producing carbon-reduced aldose compounds: The present invention provides a process capable of industrially producing 5-deoxy-L-arabinose, important as a raw material for the production of sapropterin useful as a therapeutic agent for atypical hyperphenylalaninemia, satisfactorily efficiently even with a simple production apparatus. Provided is the process for producing 5-deoxy-L-arabinose characterized by including: reacting L-rhamnose with... Agent: Drinker Biddle & Reath (dc)

20090030192 - Process for production of compound labeled with radioactive fluorine: A process for the production of [18F]fluoro-2-deoxyglucose can produce [18F]fluoro-2-deoxyglucose in a high and stable yield of synthesis. A process for the production of a compound labeled with radioactive fluorine includes the preparing a reaction solution by adding, under a hermetic condition, TATM and an inert organic solvent to a... Agent: Fitch, Even, Tabin & Flannery

20090030193 - Synthesis of vilsmeier haack reagent from di(trichlo-romethyl) carbonate for chlorination reaction: A process of preparation of Vilsmeier-Haack reagent is provided where di(trichloromethyl) carbonate reacts with N,N-dimethylformamide to form a Vilsmeier reagent, which can be used efficiently for chlorination of sucrose-6-acetate or sucrose-6-benzoate and other sucrose acylates. This process has application in the process for preparation of 1-6-Dichloro-1-6-DIDEOXY-β-Fructofuranasyl-4-chloro-4-deoxy-galactopyranoside.... Agent: The Nath Law Group

20090030194 - Process for production of glucuronic acid and/or glucuronolactone: Provided is a process, by which glucuronic acid and/or glucuronolactone can be produced in high yield, at low cost, in an easy manner and in safe. Also provided is a process for production of glucuronic acid and/or glucuronolactone which is characterized in that sucrose is oxidized to give sucrose carboxylic... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090023904 - Nucleic acid purification instrument: A pressurizing nozzle 12 is allowed to come into contact with a nucleic acid capturing column 35 so as to closely adhere to the sealing member 36 in a manner such that the sealing member 36 is compressed. Then, an aspiration fan 52 is operated and thus the air in... Agent: Mcdermott Will & Emery LLP

20090023906 - Dried oligonucleotide composition and method of producing the same: The present invention relates to a dried oligonucleotide composition and a method for producing the same. More specifically, it relates to a dried oligonucleotide composition produced by the steps comprising adding a substance for preventing the oligonucleotide from being separated and lost, which is adhesive to a storage container containing... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20090023905 - Transgenic animal model of bone mass modulation: The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide... Agent: Drinker Biddle & Reath (dc)

20090023909 - Blueberry red ringspot virus, sequences, promoters, and uses thereof: A nucleic acid sequence of the blueberry red ringspot virus is disclosed. Also disclosed are putative promoter regions of the sequence and promoter regions capable of directing transgene expression in plants, including tissue-specific expression. Also disclosed are expression vectors, transformed plant cells and plants containing a blueberry red ringspot virus... Agent: Harness, Dickey & Pierce, P.L.C

20090023907 - Sirna targeting kinesin spindle protein (ksp): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090023908 - Sirna targeting ribosomal protein s2 (rps2): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090023910 - Applications with and methods for producing selected interstrand cross-links in nucleic acids: The invention provides a method for stably cross-linking a first nucleic acid sequence selected for being stably cross-linked in the presence of a second nucleic acid sequence selected for not being stably cross-linked in a nucleic acid molecule. The method comprises providing a nucleic acid sequence that is complementary to... Agent: Hoffmann & Baron, LLP

20090023911 - Cellulose acylate film, polarizing plate, optical compensation film, and liquid crystal display device using the same: A cellulose acylate film characterized in that it has a shear rate dependency of melt viscosity of 0.1 to 2 and/or a temperature dependency of melt viscosity of 0.1 to 3. The cellulose acylate film is capable of suppressing generation of cutting wastage at the time of cutting.... Agent: Buchanan, Ingersoll & Rooney Pc

20090023912 - Water-soluble, uv-absorbing and/or flourescent components with very high isoelectric points: Water-soluble, UV-absorbing and/or fluorescing compound having an isoelectric point greater than 10, can be obtained using molecules chosen from the group of molecules consisting of those containing at least one secondary alcohol OH group with a PKa value greater than 10 and at least one amino group with a pKb... Agent: Thorpe North & Western, LLP.

20090023913 - Glucopyranosyl-substituted phenyl derivates, medicaments containing such compounds, their use and process for their manufacture: t

20090018319 - Dna sequence in plant caragana jubata with freeze tolerance: Abstract An isolated DNA sequence set forth in SEQ ID NO: 32, which is differentially expressed in apical buds of plant Caragana jubata (Pall.) under freezing conditions, is disclosed.... Agent: Dinesh Agarwal, P.C.

20090018320 - Dna detection method using molecular beacon with the use of monomer emission/excimer emission switching of fluorescent molecule: It is intended to provide a means and a method whereby a molecule for DNA detection at an elevated accuracy can be provided, different form the existing DNA detection system with the use of a molecular beacon. A molecular beacon wherein fluorescent organic groups capable of forming an excimer are... Agent: Birch Stewart Kolasch & Birch

20090018321 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090018322 - Separation of different isoforms of plasmid dna using ultrafiltration: A method of using pressure-driven ultrafiltration efficiently to separate isoforms of plasmid DNA such as is created in bioreactors known in the art.... Agent: Barbara E. Johnson, Esq.

20090018323 - Method for extracting nucleic acid from blood: The present invention relates to an improved method for isolating nucleic acids, particularly genomic desoxyribonucleic acid (DNA) from blood.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090018324 - Labeled nucleotide analogs and uses therefor: Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090018325 - Process for preparing l-nucleic acid derivatives and intermediates thereof: A novel method has been found to produce 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine as a novel useful intermediate compound. A novel method has been further found to produce thymidine from 2,2′-anhydro-1-(β-L-arabinofuranosyl)thymine. According to these methods, synthesis of various L-nucleic acid derivatives, synthesis of which has been difficult till now, is possible.... Agent: Novartis Corporate Intellectual Property

20090018326 - Cellulose acylate film and method for producing the same: A cellulose acylate film, which contains 1% to 25% by mass of a plasticizer and has a cellulose acylate composition satisfying the inequalities of 0≦X≦2.5 and 2.1≦X+Y≦3.0 (in which X is a substitution degree of acetyl group, and Y is a substitution degree of at least one group selected from... Agent: Buchanan, Ingersoll & Rooney PC

20090018327 - Sugar chain containing 4-position halogenated galactose and application thereof: c

20090012277 - Process for preparation of timosaponin b ii: A method for preparation of Timosaponin BII, which uses Chinese traditional medicine Rhizoma Anemarrhenae or fresh rhizoma or fibrous root of Anemarrhena asphodeloides Bge. as raw material, and comprises isolation of Timosaponin BII by one or more processes selected from solvent extraction, resin adsorption, polyamide chromatography, reversed phase column chromatography,... Agent: Harness, Dickey & Pierce, P.L.C

20090012278 - Promoter for hard tissue formation: The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent... Agent: Sughrue-265550

20090012279 - Polynucleotide labeling reagent: The present invention provides a new labeling reagent for preparing modified oligonucleotides and processes for their production wherein these oligonucleotides contain at least once the structure P═N—SO2-benzole-L-M-X, characterized in that L is either —(CH2)n- or polyethylene glycol, M is selected from a group consisting of —NH—, —O—, —S—, and —COO—,... Agent: Roche Diagnostics Operations Inc.

20090012281 - 6-modified bicyclic nucleic acid analogs: The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090012280 - Oligonucleotide compound and method for treating nidovirus infections: A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between... Agent: King & Spalding LLP

20090012282 - 5-methylcytosine detection, compositions and methods therefor: Compositions and methods for detecting 5-methylcytosine in a nucleic acid are disclosed. A 5-methylcytosine discriminator, which is a deoxyribonucleosidetriphosphate comprising a cytosine-pairing moiety such as a guanosine and a moiety which hinders hydrogen bonding between the cytosine-pairing moiety and a 5-methylcytosine is described. The discriminator is able to base pair... Agent: Harness, Dickey & Pierce, P.L.C

20090012283 - Cellulose acylate film and method for producing same, and retardation film, polarizer and liquid crystal display device comprising the film: A cellulose acylate film satisfying Re≧40 is produced by transporting a cellulose acylate film having a substitution degree of acyl substituted for hydroxyl group of cellulose of 2.88 or higher, and subjecting the film to heat treatment at 160° C. or higher.... Agent: Buchanan, Ingersoll & Rooney PC

20090012284 - Process for the preparation of a piroxicam: betacyclodextrin inclusion compound: The present invention relates to a process for the preparation of an inclusion compound of piroxicam with β-cyclodextrin by spray-drying, applicable on a pilot or industrial scale. The obtained product have optimal physico-chemical characteristics as well as technological and biopharmaceutical properties and it is suitable for preparing solid pharmaceutical compositions... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090012285 - Nucleic acid adsorption under low-salt conditions: Biscationic organic compounds are disclosed which promote adsorption of nucleic acids from an aqueous solution to a solid phase such as silica. Adsorption takes place under low salt conditions. Further disclosed are methods and kits suitable for nucleic acid isolation from aqueous solutions.... Agent: Roche Diagnostics Operations Inc.

20090005547 - Sirna targeting neuropilin 1 (nrp1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090005548 - Sirna targeting nuclear receptor interacting protein 1 (nrip1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090005549 - Processes and reagents for desilylation of oligonucleotides: The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another aspect of the present invention relates to a method of preparing oligonucleotides via the phosphoramidite method using an activator of... Agent: Foley Hoag, LLP

20090005550 - Polynucleotide containing a phosphate mimetic: The present invention concerns modified oligonucleotides and processes for their production wherein these oligonucleotides contain at least once the structure P═N-Acc where Acc is an electron acceptor or an electron acceptor substituted with a residue R and R is any organic substituent.... Agent: Roche Diagnostics Operations Inc.

20090005551 - Synthesis of 5-azacytidine: e

20090005553 - High shear process for dextrose production: Use of a high shear mechanical device in a process for production of starch hydrolysate by reacting starch with a hydrolytic agent makes possible a decrease in mass transfer limitations, thereby enhancing production of starch hydrolysate. A system for production of starch hydrolysate is also provided in which a reactor... Agent: Conley Rose, P.C. David A. Rose

20090005552 - System and process for starch production: Use of a high shear mechanical device in a process for production of starch by hydration and disruption of corn kernel particles in the presence of sulfur dioxide or bisulfite ions makes possible a decrease in mass transfer limitations, thereby enhancing starch production. A system for production of starch is... Agent: Conley Rose, P.C. David A. Rose

20090005554 - Reduced malto-oligosaccharides: Disclosed are a method for the reduction of an oligosaccharide mixture and an oligosaccharide mixture prepared thereby. In accordance with the disclosed invention, a mixture of oligosaccharides having a given DP profile is reduced to a DE of essentially zero by catalytically hydrogenating the mixture under reaction conditions sufficient to... Agent: Banner & Witcoff, Ltd.